Blood Collection Biorepository for Liver Disease Research

Sponsor

State University of New York at Buffalo (Other)

Overall Status

Recruiting

CT.gov ID

NCT03025074

Collaborator

(none)

1,000

Enrollment

Location

1037

Duration (Months)

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of establishing a biorepository is to provide high quality specimens (serum, plasma, buffy coat and liver tissue) for future researchers who are studying the effects that fatty liver and viral diseases have on the liver.

Condition or Disease	Intervention/Treatment	Phase
Non-Alcoholic Steatohepatitis(NASH) Hepatitis C Hepatitis B Fibrosis Cirrhosis Fatty Liver Obesity, Childhood Bariatric Surgery Candidate

Detailed Description

The Biorepository at the University at Buffalo has been established to collect biological samples from patients with various types of liver disease. The objectives of this biorepository are to stimulate collaboration between clinicians and researchers, to bolster training of junior investigators and to promote multidisciplinary integration to advance translational medicine and to improve the health of patients all over the country. The purpose of this biorepository is to support investigators and to provide them with high quality specimens to promote their efforts in new discoveries or perfecting treatment of patients with liver diseases caused by Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH), Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), and Human Immunodeficiency Virus (HIV). The goal is to obtain samples that represent patients seen in the clinics of medical centers in Western NY and from some of the rarer diseases encountered in these clinics. The ultimate goal is to develop the biorepository as Western New York's resource for clinically annotated human samples that can be used to conduct research that could lead to significant advances in patient care.

Study Design

Study Type:

Observational [Patient Registry]

Anticipated Enrollment :

1000 participants

Observational Model:

Cohort

Time Perspective:

Cross-Sectional

Official Title:

Virology, Immunology and Mechanisms of Liver Disease in Patients With Hepatitis C and Other Liver Diseases

Study Start Date :

Jul 1, 2013

Anticipated Primary Completion Date :

Dec 1, 2099

Anticipated Study Completion Date :

Dec 1, 2099

Outcome Measures

Primary Outcome Measures

Number of samples collected [52 weeks]
Total number of samples collected

Eligibility Criteria

Criteria

Ages Eligible for Study:

7 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

This protocol is to establish a biobank of blood samples from individuals with or without liver diseases including viral hepatitis, liver cancer, NASH, and negative control samples.
Children and teenagers will be special populations considered in this protocol.